We are live on ! Find out more
BCM

Bridgeway Capital Management Portfolio holdings

AUM $4.97B
1-Year Est. Return 44.96%
This Fund
S&P 500
This Quarter Est. Return
-15.26%
1 Year Est. Return
+44.96%
3 Year Est. Return
+114.45%
5 Year Est. Return
+175.29%
10 Year Est. Return
+704.01%
AUM
$7.53B
AUM Growth
-$2.75B
Cap. Flow
-$1.08B
Cap. Flow %
-14.29%
Top 10 Hldgs %
12.34%
Holding
1,547
New
122
Increased
288
Reduced
505
Closed
182

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$67.4M
2
UNP icon
Union Pacific
UNP
+$58.9M
3
LLY icon
Eli Lilly
LLY
+$58.2M
4
MKC icon
McCormick & Company Non-Voting
MKC
+$55.5M
5
PLD icon
Prologis
PLD
+$44.7M

Sector Composition

Rank Sector Weight
1 Financials 24.04%
2 Healthcare 13.43%
3 Consumer Discretionary 11.21%
4 Industrials 10.14%
5 Technology 9.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NDLS icon
1301
Noodles & Co
NDLS
$108M
$101K ﹤0.01%
1,800
-2,713
-60% -$202K
DXYN
1302
DELISTED
Dixie Group Inc
DXYN
$101K ﹤0.01%
143,200
-35,000
-20% -$43.9K
RELV
1303
DELISTED
Reliv International Inc
RELV
$101K ﹤0.01%
26,939
ACET
1304
DELISTED
Aceto Corp
ACET
$101K ﹤0.01%
+120,000
New +$215K
SMSI icon
1305
Smith Micro Software
SMSI
$16M
$100K ﹤0.01%
1,388
-1,935
-58% -$174K
QUIK icon
1306
QuickLogic
QUIK
$245M
$99K ﹤0.01%
9,629
-7,142
-43% -$92K
ZVRA icon
1307
Zevra Therapeutics
ZVRA
$622M
$98K ﹤0.01%
3,438
EGIO
1308
DELISTED
Edgio, Inc. Common Stock
EGIO
$98K ﹤0.01%
+1,043
New +$153K
OMED
1309
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$98K ﹤0.01%
130,900
LPTH icon
1310
Lightpath Technologies
LPTH
$753M
$97K ﹤0.01%
65,000
IRD
1311
Opus Genetics
IRD
$312M
$96K ﹤0.01%
2,148
+1,042
+94% +$60.9K
LIVE icon
1312
Live Ventures
LIVE
$29.5M
$92K ﹤0.01%
13,702
CHCI icon
1313
Comstock Holding Companies
CHCI
$159M
$91K ﹤0.01%
54,400
PFIN
1314
DELISTED
P&F Industries
PFIN
$90K ﹤0.01%
11,688
CRBP icon
1315
Corbus Pharmaceuticals
CRBP
$177M
$86K ﹤0.01%
493
-4,198
-89% -$838K
STKS icon
1316
The ONE Group
STKS
$56.2M
$84K ﹤0.01%
27,400
CVU icon
1317
CPI Aerostructures
CVU
$65.7M
$81K ﹤0.01%
12,700
-26,600
-68% -$189K
XTNT icon
1318
Xtant Medical Holdings
XTNT
$61.7M
$81K ﹤0.01%
50,000
UQM
1319
DELISTED
UQM Technologies, Inc.
UQM
$80K ﹤0.01%
94,000
OCC icon
1320
Optical Cable Corp
OCC
$138M
$77K ﹤0.01%
+20,100
New +$93.7K
ALTO icon
1321
Alto Ingredients
ALTO
$392M
$75K ﹤0.01%
86,900
FSI icon
1322
Flexible Solutions
FSI
$64.4M
$75K ﹤0.01%
55,707
AWX icon
1323
Avalon Holdings
AWX
$9.94M
$73K ﹤0.01%
27,375
+14,700
+116% +$45.3K
CYPH
1324
Cypherpunk Technologies Inc
CYPH
$78M
$73K ﹤0.01%
3,630
SCYX icon
1325
SCYNEXIS
SCYX
$51.2M
$72K ﹤0.01%
1,875
+625
+50% +$42.4K

Similar funds

Bridgeway Capital Management's Q4 2018 Portfolio in Review

As of Q4 2018, Bridgeway Capital Management held 1,547 positions worth $7.53B, down 27% from $10.3B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Bridgeway Capital Management withdrew a net $1.08B in Q4 2018, closing 182 positions and reducing 505 holdings. Its most notable exit was Express Scripts Holding Company, an estimated $86.6M position sold in full.

By sector, the portfolio is most concentrated in Financials at 24% of assets, up from 24% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Bridgeway Capital Management opened a new position in Eli Lilly worth $60.3M.

  • Bridgeway Capital Management's largest Q4 2018 buy was Eli Lilly: 521,450 shares worth $60.3M.
  • Bridgeway Capital Management added most to Merck in Q4 2018, an estimated $67.4M increase.
  • Bridgeway Capital Management's biggest Q4 2018 reduction was ON Semiconductor, cutting an estimated $54.9M.
  • Bridgeway Capital Management fully exited Express Scripts Holding Company in Q4 2018, selling an estimated $86.6M.
  • Bridgeway Capital Management's ten largest holdings make up 12% of its $7.53B portfolio in Q4 2018.
  • Bridgeway Capital Management opened 122 new positions and closed 182 in Q4 2018.
  • Bridgeway Capital Management's portfolio value fell 27% quarter-over-quarter to $7.53B.

Based on Bridgeway Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.